GSK’s (GSK) “Buy” Rating Reaffirmed at Berenberg Bank

GSK (LON:GSK)‘s stock had its “buy” rating reaffirmed by equities research analysts at Berenberg Bank in a report issued on Tuesday, Digital Look reports. They currently have a GBX 2,200 target price on the stock. Berenberg Bank‘s target price points to a potential upside of 20.12% from the stock’s previous close.

GSK has been the topic of a number of other research reports. Royal Bank Of Canada began coverage on GSK in a report on Tuesday, September 8th. They issued a “sector perform” rating and a GBX 1,975 price objective on the stock. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 2,000 target price on shares of GSK in a research note on Thursday, October 29th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a report on Tuesday, October 20th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, GSK has a consensus rating of “Hold” and an average target price of GBX 2,064.38.

GSK Stock Up 0.4%

Shares of LON:GSK opened at GBX 1,831.50 on Tuesday. The company has a market cap of £73.39 billion, a price-to-earnings ratio of 15.55, a PEG ratio of 1.24 and a beta of 0.28. The firm’s 50-day simple moving average is GBX 1,843.60 and its 200-day simple moving average is GBX 1,948.72. The company has a quick ratio of 0.73, a current ratio of 0.86 and a debt-to-equity ratio of 126.38. GSK has a fifty-two week low of GBX 1,690 and a fifty-two week high of GBX 2,282.

GSK (LON:GSK) last posted its quarterly earnings results on Wednesday, October 28th. The company reported GBX 54.60 earnings per share (EPS) for the quarter. The firm had revenue of GBX 888.70 billion during the quarter. GSK had a net margin of 12.97% and a return on equity of 24.64%. As a group, equities research analysts predict that GSK will post 175.98 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Anne Beal purchased 637 shares of GSK stock in a transaction dated Friday, September 18th. The stock was bought at an average cost of GBX 4,985 per share, for a total transaction of £31,754.45. Also, insider Jonathan Symonds purchased 1,500 shares of the firm’s stock in a transaction dated Friday, September 18th. The shares were purchased at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Over the last quarter, insiders have bought 2,151 shares of company stock valued at $6,021,921. Insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.